Concepts (159)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cardiovascular Diseases | 4 | 2025 | 749 | 1.630 |
Why?
|
| Chronic Disease | 6 | 2024 | 549 | 1.620 |
Why?
|
| Puerto Rico | 16 | 2025 | 1413 | 1.130 |
Why?
|
| Life Style | 4 | 2019 | 334 | 1.060 |
Why?
|
| Interferon-alpha | 3 | 2012 | 43 | 0.880 |
Why?
|
| Hepatitis C, Chronic | 3 | 2012 | 44 | 0.840 |
Why?
|
| Cyclonic Storms | 2 | 2022 | 80 | 0.830 |
Why?
|
| Epidemiologic Studies | 2 | 2021 | 33 | 0.820 |
Why?
|
| Research Design | 2 | 2025 | 385 | 0.770 |
Why?
|
| Health Status | 4 | 2024 | 442 | 0.750 |
Why?
|
| Liver Cirrhosis | 3 | 2007 | 67 | 0.700 |
Why?
|
| Stress, Psychological | 2 | 2025 | 661 | 0.670 |
Why?
|
| Polyethylene Glycols | 3 | 2012 | 108 | 0.660 |
Why?
|
| Hepatitis C | 3 | 2007 | 139 | 0.630 |
Why?
|
| Ribavirin | 2 | 2012 | 21 | 0.630 |
Why?
|
| Antiviral Agents | 3 | 2012 | 195 | 0.600 |
Why?
|
| Adult | 20 | 2025 | 13872 | 0.560 |
Why?
|
| Risk Factors | 7 | 2025 | 3994 | 0.540 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2018 | 465 | 0.490 |
Why?
|
| Health Behavior | 2 | 2018 | 575 | 0.490 |
Why?
|
| Diet | 7 | 2023 | 826 | 0.480 |
Why?
|
| HIV Infections | 6 | 2008 | 2586 | 0.480 |
Why?
|
| Aged | 11 | 2025 | 8214 | 0.470 |
Why?
|
| Middle Aged | 16 | 2025 | 12222 | 0.470 |
Why?
|
| Prevalence | 4 | 2022 | 1612 | 0.440 |
Why?
|
| Stilbenes | 1 | 2014 | 44 | 0.430 |
Why?
|
| Hepacivirus | 2 | 2012 | 74 | 0.420 |
Why?
|
| Cross-Sectional Studies | 10 | 2023 | 3156 | 0.420 |
Why?
|
| Female | 19 | 2025 | 24698 | 0.410 |
Why?
|
| Male | 17 | 2025 | 23409 | 0.390 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2014 | 241 | 0.370 |
Why?
|
| Humans | 24 | 2025 | 43102 | 0.360 |
Why?
|
| Residence Characteristics | 2 | 2025 | 363 | 0.310 |
Why?
|
| Virus Replication | 1 | 2012 | 318 | 0.310 |
Why?
|
| HIV | 2 | 2006 | 100 | 0.300 |
Why?
|
| Adolescent | 4 | 2025 | 6081 | 0.270 |
Why?
|
| Motor Activity | 2 | 2014 | 437 | 0.250 |
Why?
|
| Liver | 2 | 2007 | 511 | 0.250 |
Why?
|
| Young Adult | 3 | 2025 | 5080 | 0.250 |
Why?
|
| Treatment Outcome | 5 | 2012 | 1604 | 0.240 |
Why?
|
| Energy Intake | 3 | 2023 | 164 | 0.240 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2005 | 44 | 0.230 |
Why?
|
| Anti-Ulcer Agents | 1 | 2005 | 7 | 0.230 |
Why?
|
| Penicillins | 1 | 2005 | 10 | 0.230 |
Why?
|
| Drug Hypersensitivity | 1 | 2005 | 6 | 0.230 |
Why?
|
| Helicobacter Infections | 1 | 2005 | 86 | 0.220 |
Why?
|
| Sex Factors | 2 | 2024 | 1028 | 0.210 |
Why?
|
| Anti-Retroviral Agents | 1 | 2005 | 160 | 0.210 |
Why?
|
| Anti-Infective Agents | 1 | 2005 | 75 | 0.210 |
Why?
|
| Helicobacter pylori | 1 | 2005 | 118 | 0.210 |
Why?
|
| Mice | 2 | 2014 | 6644 | 0.210 |
Why?
|
| Viral Load | 4 | 2012 | 348 | 0.200 |
Why?
|
| Drug Therapy, Combination | 3 | 2012 | 234 | 0.200 |
Why?
|
| Resilience, Psychological | 1 | 2025 | 106 | 0.200 |
Why?
|
| Recombinant Proteins | 3 | 2012 | 518 | 0.200 |
Why?
|
| Feeding Behavior | 2 | 2023 | 469 | 0.190 |
Why?
|
| RNA, Viral | 3 | 2012 | 321 | 0.190 |
Why?
|
| Socioeconomic Factors | 3 | 2022 | 1234 | 0.190 |
Why?
|
| Eating | 2 | 2023 | 167 | 0.180 |
Why?
|
| Risk Assessment | 1 | 2024 | 863 | 0.170 |
Why?
|
| Age Factors | 1 | 2024 | 1154 | 0.170 |
Why?
|
| Vegetables | 1 | 2020 | 147 | 0.150 |
Why?
|
| Disease Progression | 3 | 2007 | 667 | 0.150 |
Why?
|
| Housing, Animal | 1 | 2018 | 12 | 0.140 |
Why?
|
| Sunlight | 1 | 2018 | 48 | 0.140 |
Why?
|
| Incidence | 1 | 2021 | 1078 | 0.140 |
Why?
|
| Food Supply | 1 | 2019 | 122 | 0.140 |
Why?
|
| Longitudinal Studies | 1 | 2021 | 1063 | 0.130 |
Why?
|
| Medical Records | 1 | 2017 | 48 | 0.130 |
Why?
|
| Interferons | 2 | 2007 | 40 | 0.130 |
Why?
|
| Prospective Studies | 1 | 2021 | 1600 | 0.130 |
Why?
|
| Emigrants and Immigrants | 1 | 2018 | 158 | 0.120 |
Why?
|
| Vitamin D | 1 | 2018 | 196 | 0.120 |
Why?
|
| Diet Surveys | 3 | 2020 | 99 | 0.120 |
Why?
|
| Reference Standards | 1 | 2014 | 55 | 0.110 |
Why?
|
| Calibration | 1 | 2014 | 63 | 0.110 |
Why?
|
| Health Status Disparities | 1 | 2021 | 719 | 0.110 |
Why?
|
| Biopsy | 2 | 2005 | 177 | 0.110 |
Why?
|
| Tamoxifen | 1 | 2014 | 69 | 0.100 |
Why?
|
| Spinal Cord Injuries | 1 | 2014 | 69 | 0.100 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 611 | 0.100 |
Why?
|
| Molecular Structure | 1 | 2014 | 570 | 0.100 |
Why?
|
| Retrospective Studies | 2 | 2012 | 2544 | 0.090 |
Why?
|
| Estradiol | 1 | 2014 | 268 | 0.090 |
Why?
|
| Neuroprotective Agents | 1 | 2014 | 269 | 0.080 |
Why?
|
| Kinetics | 1 | 2012 | 695 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2012 | 375 | 0.080 |
Why?
|
| Antioxidants | 1 | 2014 | 443 | 0.080 |
Why?
|
| Dietary Fats | 2 | 2020 | 117 | 0.080 |
Why?
|
| Glutamate-Cysteine Ligase | 1 | 2009 | 17 | 0.070 |
Why?
|
| Plasmodium berghei | 1 | 2009 | 34 | 0.070 |
Why?
|
| Equipment and Supplies | 1 | 2008 | 10 | 0.070 |
Why?
|
| Glutathione | 1 | 2009 | 171 | 0.070 |
Why?
|
| Malaria | 1 | 2009 | 90 | 0.070 |
Why?
|
| Cerebrospinal Fluid | 1 | 2007 | 20 | 0.070 |
Why?
|
| Injections, Subcutaneous | 1 | 2006 | 36 | 0.060 |
Why?
|
| Drug Administration Schedule | 1 | 2007 | 153 | 0.060 |
Why?
|
| Time Factors | 2 | 2014 | 1857 | 0.060 |
Why?
|
| Acute Disease | 1 | 2006 | 155 | 0.060 |
Why?
|
| Cognition Disorders | 1 | 2007 | 243 | 0.060 |
Why?
|
| Aged, 80 and over | 1 | 2012 | 2853 | 0.060 |
Why?
|
| Duodenal Ulcer | 1 | 2005 | 5 | 0.060 |
Why?
|
| Tetracycline | 1 | 2005 | 17 | 0.060 |
Why?
|
| Gastritis | 1 | 2005 | 13 | 0.060 |
Why?
|
| Metronidazole | 1 | 2005 | 16 | 0.060 |
Why?
|
| Animals | 4 | 2018 | 16992 | 0.060 |
Why?
|
| Proteomics | 1 | 2007 | 378 | 0.060 |
Why?
|
| Reproducibility of Results | 1 | 2008 | 1081 | 0.050 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2005 | 229 | 0.050 |
Why?
|
| Starch | 1 | 2023 | 12 | 0.050 |
Why?
|
| Carbohydrates | 1 | 2023 | 32 | 0.050 |
Why?
|
| Comorbidity | 1 | 2006 | 737 | 0.050 |
Why?
|
| Logistic Models | 1 | 2006 | 1009 | 0.050 |
Why?
|
| Follow-Up Studies | 1 | 2005 | 1067 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 1 | 2005 | 432 | 0.040 |
Why?
|
| Least-Squares Analysis | 1 | 2020 | 45 | 0.040 |
Why?
|
| Dietary Proteins | 1 | 2020 | 35 | 0.040 |
Why?
|
| Dietary Fiber | 1 | 2020 | 51 | 0.040 |
Why?
|
| Base Sequence | 1 | 2022 | 983 | 0.040 |
Why?
|
| Linear Models | 1 | 2020 | 317 | 0.040 |
Why?
|
| Food Analysis | 1 | 2019 | 34 | 0.040 |
Why?
|
| Dominican Republic | 1 | 2018 | 20 | 0.040 |
Why?
|
| Nutritional Status | 1 | 2019 | 119 | 0.040 |
Why?
|
| Caribbean Region | 1 | 2018 | 79 | 0.030 |
Why?
|
| Macaca mulatta | 1 | 2018 | 139 | 0.030 |
Why?
|
| Body Weight | 1 | 2018 | 429 | 0.030 |
Why?
|
| Sleep | 1 | 2018 | 185 | 0.030 |
Why?
|
| Drug Implants | 1 | 2014 | 20 | 0.030 |
Why?
|
| Nerve Fibers, Myelinated | 1 | 2014 | 16 | 0.030 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2014 | 19 | 0.030 |
Why?
|
| Estrogen Antagonists | 1 | 2014 | 30 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2014 | 107 | 0.030 |
Why?
|
| Spinal Cord | 1 | 2014 | 114 | 0.020 |
Why?
|
| Estrogen Receptor alpha | 1 | 2014 | 121 | 0.020 |
Why?
|
| Alcohol Drinking | 1 | 2018 | 609 | 0.020 |
Why?
|
| Smoking | 1 | 2018 | 1024 | 0.020 |
Why?
|
| Depression | 1 | 2018 | 863 | 0.020 |
Why?
|
| United States | 1 | 2022 | 5205 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 989 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2014 | 532 | 0.020 |
Why?
|
| Sporozoites | 1 | 2009 | 6 | 0.020 |
Why?
|
| Oocysts | 1 | 2009 | 5 | 0.020 |
Why?
|
| Gene Targeting | 1 | 2009 | 39 | 0.020 |
Why?
|
| Anopheles | 1 | 2009 | 21 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 113 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2014 | 1766 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2009 | 160 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2009 | 256 | 0.020 |
Why?
|
| Erythrocytes | 1 | 2009 | 126 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2014 | 1003 | 0.020 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2007 | 78 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2009 | 575 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2007 | 284 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2007 | 280 | 0.020 |
Why?
|
| Gene Expression | 1 | 2009 | 701 | 0.010 |
Why?
|
| Mitochondria | 1 | 2009 | 523 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2007 | 1542 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2007 | 1759 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2009 | 1455 | 0.010 |
Why?
|
Rodríguez-Orengo's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(159)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(17)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_